SuperGen Inc. Announces Intent to Withdraw the Registration Statement for Public Offering of Shares of Common Stock

SuperGen Inc. Announces Intent to Withdraw the Registration Statement for Public Offering of Shares of Common Stock

SuperGen Completes Submission of New Drug Application (NDA) for Orathecin™ As an Oral Treatment for Pancreatic Cancer

SuperGen Completes Submission of New Drug Application (NDA) for Orathecin™ As an Oral Treatment for Pancreatic Cancer

Published Data Suggests SuperGen’s Nipent®, as Part of a Combination Preparative Regimen, is Active in Allogeneic Bone Marrow Transplant Patients with Myelodysplastic Syndrome

Published Data Suggests SuperGen’s Nipent®, as Part of a Combination Preparative Regimen, is Active in Allogeneic Bone Marrow Transplant Patients with Myelodysplastic Syndrome